Clinical trial
Phase II Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)
NCT02667574 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)
- Lead sponsor
- University Hospital, Lille
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 18, 2014
- Completion date
- July 15, 2020
- Enrollment
- 55 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.